Tiebang Kang

14.0k total citations · 3 hit papers
156 papers, 8.9k citations indexed

About

Tiebang Kang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Tiebang Kang has authored 156 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Molecular Biology, 60 papers in Oncology and 47 papers in Cancer Research. Recurrent topics in Tiebang Kang's work include RNA modifications and cancer (30 papers), Epigenetics and DNA Methylation (23 papers) and Cancer-related gene regulation (21 papers). Tiebang Kang is often cited by papers focused on RNA modifications and cancer (30 papers), Epigenetics and DNA Methylation (23 papers) and Cancer-related gene regulation (21 papers). Tiebang Kang collaborates with scholars based in China, United States and Hong Kong. Tiebang Kang's co-authors include Ruhua Zhang, Yuanzhong Wu, Binhua P. Zhou, Yi-Xin Zeng, Duanqing Pei, Dan Liao, Wuguo Deng, Li Zhong, Xin Wang and Dingbo Shi and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Tiebang Kang

151 papers receiving 8.8k citations

Hit Papers

Loss of FBP1 by Snail-Mediated Repression Provides Metabo... 2013 2026 2017 2021 2013 2019 2020 200 400 600

Peers

Tiebang Kang
Karen Blyth United Kingdom
Ana I. Robles United States
Xinbin Chen United States
Yun‐Sil Lee South Korea
Giovanni Melillo United States
Tiebang Kang
Citations per year, relative to Tiebang Kang Tiebang Kang (= 1×) peers Jukka Westermarck

Countries citing papers authored by Tiebang Kang

Since Specialization
Citations

This map shows the geographic impact of Tiebang Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiebang Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiebang Kang more than expected).

Fields of papers citing papers by Tiebang Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiebang Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiebang Kang. The network helps show where Tiebang Kang may publish in the future.

Co-authorship network of co-authors of Tiebang Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Tiebang Kang. A scholar is included among the top collaborators of Tiebang Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiebang Kang. Tiebang Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Xiaobo, Qiuxia Wang, Denghui Wei, et al.. (2025). Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1. Cell Research. 35(7). 497–509. 3 indexed citations
2.
Zhou, Liwen, Ting Li, Ruhua Zhang, et al.. (2024). Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer. Advanced Science. 11(22). e2310146–e2310146. 11 indexed citations
3.
Li, Fanying, Kailin Yang, Xinya Gao, et al.. (2024). A peptide encoded by upstream open reading frame of MYC binds to tropomyosin receptor kinase B and promotes glioblastoma growth in mice. Science Translational Medicine. 16(767). eadk9524–eadk9524. 5 indexed citations
4.
Luo, Li, Denghui Wei, Yihui Pan, et al.. (2023). MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR. Cancer Communications. 43(7). 808–833. 10 indexed citations
5.
Xiong, Xinxin, Siyu Chen, Jianfei Shen, et al.. (2022). Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. Signal Transduction and Targeted Therapy. 7(1). 99–99. 52 indexed citations
6.
Cheng, Rongjie, Fanying Li, Maolei Zhang, et al.. (2022). A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cell Research. 33(1). 30–45. 40 indexed citations
7.
Fu, Lingyi, Sen Li, Weiwei Xiao, et al.. (2021). DGKA Mediates Resistance to PD-1 Blockade. Cancer Immunology Research. 9(4). 371–385. 23 indexed citations
8.
Wen, Shijun, Fang Liu, Zijian Zhang, et al.. (2021). CRISPR/Cas9 screening identifies a kinetochore‐microtubule dependent mechanism for Aurora‐A inhibitor resistance in breast cancer. Cancer Communications. 41(2). 121–139. 30 indexed citations
9.
Tian, Xiao‐Peng, Jun Cai, Shu‐Yun Ma, et al.. (2020). BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma. Cancer Communications. 40(6). 245–259. 19 indexed citations
10.
Liao, Dan, Li Zhong, Junqiang Yin, et al.. (2020). Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. Nature Cell Biology. 22(7). 868–881. 47 indexed citations
11.
Zhang, Qi, Jian Liu, Shuang Wang, et al.. (2019). Targeted nanoparticle-mediated LHPP for melanoma treatment. SHILAP Revista de lepidopterología. 3 indexed citations
12.
Chen, Xin, Jiaxing Zhang, Junhang Luo, et al.. (2018). CSTF2-Induced Shortening of the RAC1 3′UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder. Cancer Research. 78(20). 5848–5862. 55 indexed citations
13.
Yang, Qi, Meng-Xia Zhang, Xiong Zou, et al.. (2017). A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy. Clinical Cancer Research. 24(3). 648–658. 26 indexed citations
14.
Wang, Xin, Liping Li, Yuanzhong Wu, et al.. (2016). CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma. Cancer Research. 76(24). 7277–7289. 69 indexed citations
15.
Liao, Dan, Li Zhong, Ru-Hua Zhang, et al.. (2015). Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway. Clinical Cancer Research. 21(23). 5349–5359. 101 indexed citations
16.
Shi, Dingbo, Fang‐Yun Xie, Yun Zhang, et al.. (2013). TFAP2A Regulates Nasopharyngeal Carcinoma Growth and Survival by Targeting HIF-1α Signaling Pathway. Cancer Prevention Research. 7(2). 266–277. 57 indexed citations
17.
Shi, Dingbo, Wei Guo, Lingyi Fu, et al.. (2012). Nicotine Promotes Proliferation of Human Nasopharyngeal Carcinoma Cells by Regulating α7AChR, ERK, HIF-1α and VEGF/PEDF Signaling. PLoS ONE. 7(8). e43898–e43898. 62 indexed citations
18.
Zhang, Hui, Qi‐Sheng Feng, Manbo Cai, et al.. (2012). The propensity for tumorigenesis in human induced pluripotent stem cells is related with genomic instability. Chinese Journal of Cancer. 32(4). 205–212. 20 indexed citations
19.
Gao, Shijuan, Liping Song, Jiandong Li, et al.. (2012). Influenza A virus-encoded NS1 virulence factor protein inhibits innate immune response by targeting IKK. Cellular Microbiology. 14(12). 1849–1866. 91 indexed citations
20.
Xu, Da-Zhong, et al.. (1997). [Dynamic study of anti-NS5 and ALT in post-transfusion hepatitis C].. PubMed. 11(4). 344–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026